DiaMedica Therapeutics Inc.
DMAC
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious vascular and ischemic diseases. Its current pipeline is centered on DM199, a recombinant form of human tissue kallikrein-1 being studied for acute ischemic stroke, preeclampsia, fetal growth restriction, and other conditions linked to impaired blood flow. The company also advances DM300, a recombinant human ulinastatin candidate in preclinical development for inflammatory disorders. DiaMedica Therapeutics serves the neuroscience, women’s health, renal, and inflammatory disease areas through therapies designed to address significant unmet medical needs. Headquartered in Minneapolis, Minnesota, DiaMedica Therapeutics Inc. operates as a specialized biotech platform focused on recombinant protein-based drug development.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$38M
▼ -34.0% YoY
Op. Margin
–
ROIC
-55.79%
▼ -10.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$32M
▼ -31.7% YoY
Op. Cash Flow (TTM)
-$32M
▼ -31.5% YoY
Net Debt
-$60M
Net Cash Position
Cash & Equiv.
$60M
Continue Research
Peers
Biotechnology · Pick stocks to compare with DMAC
Held by ETFs
DMAC is in 3 US ETFs. The largest of them, with DMAC's weight in each:
DiaMedica Therapeutics (DMAC) in three numbers
Questions about DiaMedica Therapeutics
Is DiaMedica Therapeutics a high-quality business?
DiaMedica Therapeutics scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from company filings. Its best check is net debt at -$60M, and its weakest is return on capital at -55.8%. The Quality tab shows every check against its target.
Does DiaMedica Therapeutics (DMAC) pay a dividend?
No. DiaMedica Therapeutics (DMAC) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing DMAC
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.